These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9482531)

  • 21. Pact with the devil: alemtuzumab therapy, immune suppression and infectious complications in chronic lymphocytic leukemia.
    Antohe I; Dascalescu A; Burcoveanu C; Ghiorghiu D; Dascalu A; Danaila C
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(1):92-5. PubMed ID: 24741782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
    Eichhorst BF; Busch R; Schweighofer C; Wendtner CM; Emmerich B; Hallek M;
    Br J Haematol; 2007 Jan; 136(1):63-72. PubMed ID: 17083342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
    Tam C; Seymour JF; Brown M; Campbell P; Scarlett J; Underhill C; Ritchie D; Bond R; Grigg AP
    Haematologica; 2005 May; 90(5):700-2. PubMed ID: 15921393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia.
    Nishida H; Murase T; Ueno H; Park JW; Yano T; Ikeda Y
    Leuk Res; 2006 Dec; 30(12):1589-90. PubMed ID: 16542723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pentostatin in chronic lymphocytic leukemia.
    Sauter C; Lamanna N; Weiss MA
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1217-22. PubMed ID: 18721115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
    Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia.
    Tadmor T; Welslau M; Hus I
    Expert Rev Hematol; 2018 Jan; 11(1):57-70. PubMed ID: 29160119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infectious complications in chronic lymphocytic leukaemia.
    Morra E; Nosari A; Montillo M
    Hematol Cell Ther; 1999 Aug; 41(4):145-51. PubMed ID: 10543369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
    Stelitano C; Morabito F; Kropp MG; Callea V; Iuliano F; Oriana V; Levato D; Nobile F; Molica S; Brugiatelli M
    Haematologica; 1999 Apr; 84(4):317-23. PubMed ID: 10190945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Successful combined treatment with rituximab and high dose immunoglobulin in a patient with chronic lymphocytic leukemia with fludarabine-induced severe immune thrombocytopenia].
    Telek B; Batár P; Uvardy M
    Orv Hetil; 2005 Aug; 146(34):1791-3. PubMed ID: 16184881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Caring for patients with chronic lymphocytic leukemia.
    Elphee EE
    Clin J Oncol Nurs; 2008 Jun; 12(3):417-23. PubMed ID: 18515240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebral toxoplasmosis in a patient with chronic lymphocytic leukaemia treated with fludarabine.
    Bacchu S; Fegan C; Neal J
    Br J Haematol; 2007 Nov; 139(3):349. PubMed ID: 17784883
    [No Abstract]   [Full Text] [Related]  

  • 33. Autoimmune complications of chronic lymphocytic leukemia.
    Hamblin TJ
    Semin Oncol; 2006 Apr; 33(2):230-9. PubMed ID: 16616070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Infectious complications of immune deficiencies].
    Chandesris MO; Lanternier F; Lecuit M; Lortholary O
    Rev Prat; 2007 Oct; 57(15):1653-64. PubMed ID: 18080423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
    Kasamon YL; Flinn IW; Grever MR; Diehl LF; Garrett-Mayer E; Goodman SN; Lucas MS; Byrd JC
    Clin Cancer Res; 2005 Dec; 11(23):8413-7. PubMed ID: 16322303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment.
    Molica S
    Leuk Lymphoma; 1994 Apr; 13(3-4):203-14. PubMed ID: 8049645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
    Varga F; Lehoczky D; Demeter J
    Orv Hetil; 1999 Aug; 140(31):1731-5. PubMed ID: 10463032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Purine analogue-based chemotherapy regimens for second-line therapy in patients with chronic lymphocytic leukemia.
    Lamanna N; Weiss MA
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S44-9. PubMed ID: 16549114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes.
    Molteni A; Nosari A; Montillo M; Cafro A; Klersy C; Morra E
    Haematologica; 2005 Aug; 90(8):1145-7. PubMed ID: 16079122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.